Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, is on a mission to develop and market breakthrough product candidates for the treatment of central nervous system diseases. The company's lead product candidate, the roluperidone (MIN-101), is currently being assessed for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. has also developed the MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has recently submitted its New Drug Application (NDA) for the roluperidone and entered into a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally, excluding Asia. Since its inception in 2007, Minerva Neurosciences, Inc. has undergone several changes, including a name change from Cyrenaic Pharmaceuticals, Inc. in 2013, before settling its headquarters in Waltham, Massachusetts.